Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Trastuzumab has been used for the treatment of HER2-overexpressing breast cancer for more than a decade, but the mechanisms of action for the therapy are still being actively investigated. Ab-dependent cell-mediated cytotoxicity mediated by NK cells is well recognized as one of the key mechanisms of action for trastuzumab, but trastuzumab-mediated Ab-dependent cellular phagocytosis (ADCP) has not been established. In this study, we demonstrate that macrophages, by way of phagocytic engulfment, can mediate ADCP and cancer cell killing in the presence of trastuzumab. Increased infiltration of macrophages in the tumor tissue was associated with enhanced efficacy of trastuzumab whereas depletion of macrophages resulted in reduced antitumor efficacy in mouse xenograft tumor models. Among the four mouse FcγRs, FcγRIV exhibits the strongest binding affinity to trastuzumab. Knockdown of FcγRIV in mouse macrophages reduced cancer cell killing and ADCP activity triggered by trastuzumab. Consistently, an upregulation of FcγRIV expression by IFN-γ triggered an increased ADCP activity by trastuzumab. In an analogous fashion, IFN-γ priming of human macrophages increased the expression of FcγRIII, the ortholog of murine FcγRIV, and increased trastuzumab-mediated cancer cell killing. Thus, in two independent systems, the results indicated that activation of macrophages in combination with trastuzumab can serve as a therapeutic strategy for treating high HER2 breast cancer by boosting ADCP killing of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2-targeting mAbs also elicit antibody-dependent cellular phagocytosis (ADCP), involving the clearance of antibodybound tumor cells by macrophages (Shi et al., 2015), a phenomenon that may be accompanied by macrophage polarization towardanM2-like immunosuppressive phenotype (Su et al., 2018).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Shi et al., 2015
In the citing paper
“induction of ADCP of HER2-expressing cancer cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Shi et al., 2015
Citations
Cites
2 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301 · cited 1×
“Other mechanisms of action of trastuzumab, including downregulation of HER2 expression (6) and inhibition of HER2 oncogenic signaling (2, 4), might also be involved.”
BackgroundRetractedKohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226 · cited 1×
“Therefore, antitumor efficacy of trastuzumab in the mouse group with macrophage depletion by clodrosome might be contributed by an NK cell– mediated ADCC effect, as ADCC as a mechanism of action for trastuzumab was reported previously (27, 29).”
BackgroundRetractedInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Studies have shown that mice with Fcg-chain knockout (g) or knockout of individual activating FcgRs lost immune effector functions of Abs and resulted in reduced antitumor efficacy of trastuzumab (22, 32, 33).”
BackgroundNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“Other mechanisms of action of trastuzumab, including downregulation of HER2 expression (6) and inhibition of HER2 oncogenic signaling (2, 4), might also be involved.”
BackgroundDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037 · cited 1×
“It has been shown that FcgRIV is important in mediating the function of anticancer Ab (IgG2a) in the model of lung and liver metastases using murine melanoma cells, and in an anti-CD20 Abdependent B cell depletion model (24, 36, 37).”
BackgroundMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“Clinical studies have implicated the important role of FcgRIII in trastuzumab efficacy (38), even though function of FcgRIII on NK cells is considered mainly to contribute to cancer cell killing through ADCC (39).”
BackgroundBone Marrow-Derived Macrophages (BMM): Isolation and Applications
Weischenfeldt, J., & Porse, B. (2008) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot5080 · Cited by 955 · cited 2×
“Briefly, the isolated bone marrow cells were cultured in complete RPMI 1640 medium supplemented with 10% FCS and 30% pretested conditioned medium from the L929 cell line as a source of M-CSF for 5 d (17).”
BackgroundMethodEngineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803 · cited 1×
“In this study, we demonstrated that activated macrophages readily phagocytosed trastuzumab-coated cancer cells (ADCP) and mediated Ab-dependent cancer cell killing in coculture conditions in vitro, and the results are consistent with the study reported previously (16).”
ResultFcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660 · cited 4×
“FcgRIV binds to mouse IgG2a and IgG2b with intermediate affinity, but it has no detectable binding to mouse IgG1 or IgG3 (22).”
BackgroundInfluentialThe function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Cited by
Items 101–200 of 202
Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?
Theocharis, S. E., Tasoulas, J., Masaoutis, C., Kokkali, S., & Klijanienko, J. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1804863 · Cited by 18
“HER2 signaling in SGC is not fully understood, extrapolated data from breast and prostate cancer suggest that TME mediates the therapeutic effect of ADT and anti-HER2 therapy [100,101,103,104].”
BackgroundShibuya, M., Tamiya, S., Kawai, A., Hirai, T., Cragg, M. S., & Yoshioka, Y. (2021) · iScience · doi:10.1016/j.isci.2021.103131 · Cited by 20
“It also remains unclear why the expression of activating FcgRs is not changed by IFN-g, because it is reported that the expression of activating FcgRs is upregulated in response to IFN-g stimulation in macrophages (Shi et al., 2015).”
BackgroundBirts, C. N., Savva, C., Laversin, S. A., Lefas, A. Y., Krishnan, J. V., Schapira, A., Ashton‐Key, M., Crispin, M., Johnson, P., Blaydes, J. P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11696-6 · Cited by 18
Wimana, Z., Gebhart, G., Guiot, T., Vanderlinden, B., Larsimont, D., Doumont, G., Simaeys, G. V., Goldman, S., Flamen, P., & Ghanem, G. (2017) · Oncotarget · doi:10.18632/oncotarget.17015 · Cited by 18
“, 5mg/kg [37, 38]) (n = 10), (3) the NS group receiving sweetened drinking water supplemented with NAC and saline i.”
MethodHER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model
Juul, C. A., Engel, T. B., Fliedner, F. P., Ringgaard, L., Eliasen, R., Melander, F., Bak, M., Kjær, A., Henriksen, J. R., Elema, D. R., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.005 · Cited by 17
Single‐Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics
Li, R., Atari, A., Prytyskach, M., Garlin, M. A., Weissleder, R., & Miller, M. A. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23872 · Cited by 18
“In the case of Tzm, cell-intrinsic effects include HER2 binding and subsequent inhibition of oncogenic kinase signaling (18), while cell-extrinsic effects include the Fc (fragment crystallizable region)-mediated roles that the immune system plays in response to mAb binding, such as antibody-dependent cellmediated cyto…”
BackgroundMaadi, H., & Wang, Z. (2022) · Cells · doi:10.3390/cells11244093 · Cited by 21
Rediti, M., Fimereli, D., Mileva, M., Wimana, Z., Venet, D., Flamen, P., Guiot, T., de Vries, E. G. E., Schroder, C. P., van Oordt, C. W. M. D. H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1007 · Cited by 16
Deligne, C., Milcent, B., Josseaume, N., Teillaud, J., & Sibéril, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00950 · Cited by 16
SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells
Bahri, M., Kailayangiri, S., Vermeulen, S., Galopin, N., Rössig, C., Paris, F., Fougeray, S., & Birklé, S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02968-7 · Cited by 16
“The two-color flow cytometry ADCP assay was performed as described previously with minor modifications [26].”
MethodCD47 inhibits phagocytosis through Vav dephosphorylation
Miller, W. D., Manion, A., Mishra, A. K., Sheedy, C. J., Bond, A., Gardner, B. M., Montell, D. J., & Morrissey, M. A. (2025) · The Journal of Cell Biology · doi:10.1083/jcb.202502206 · Cited by 16
Panaampon, J., Sungwan, P., Fujikawa, S., Sampattavanich, S., Jirawatnotai, S., & Okada, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112612 · Cited by 16
Cha, E. B., Shin, K. K., Seo, J., & Oh, D. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.8.024 · Cited by 15
“It has been reported that the phagocytic ability of macrophages plays an important role in anti-cancer therapy, using monoclonal antibodies, such as rituximab, trastuzumab, daratumumab, and elotuzumab (2-5).”
BackgroundIlieva, K. M., Fazekas, J., Achkova, D., Dodev, T. S., Mele, S., Crescioli, S., Bax, H. J., Cheung, A., Karagiannis, P., Corrêa, I., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01112 · Cited by 15
Nersesian, S., Arseneau, R. J., Mejia, J. P., Lee, S. N., Westhaver, L. P., Griffiths, N. W., Grantham, S. R., Meunier, L., Communal, L., Mukherjee, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1307873 · Cited by 14
“CD16a expression in macrophages, including tumor-B associated macrophages, has been associated with an “ M1 ” -like phenotype, which promotes in fl ammation via cytokine release and antigen presentation (38).”
BackgroundChe, Y., Zhang, Y., Wang, D., Liu, H., Shen, D., & Luo, Y. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s212610 · Cited by 14
Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications
Kwok, C., & Nolan, M. T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1150569 · Cited by 15
“It also triggers antibody-dependent cell-mediated cytotoxicity—increased antigen presentation by cancer cells via upregulation of MHC molecules (62), as well as increased activation of dendritic cells (63), natural killer cells (64), and macrophages (65).”
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
Song, P. N., Mansur, A., Dugger, K. J., Davis, T. R., Howard, G. R., Yankeelov, T. E., & Sorace, A. G. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01625-w · Cited by 18
Hu, L., Zhang, S., Sienkiewicz, J., Zhou, H., Berahovich, R., Sun, J., Li, M., Ocampo, A., Liu, X., Huang, Y., et al. (2024) · Vaccines · doi:10.3390/vaccines12070808 · Cited by 15
“Trastuzumab was derived from the murine anti-HER2 mAb 4D5, which binds to the extracellular domain of HER2, thereby blocking HER2 signaling and inducing antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) [31,32].”
BackgroundMethodLu, Y., Tong, Y., Fei, X., Chen, X., & Shen, K. (2023) · Cancer Medicine · doi:10.1002/cam4.6290 · Cited by 13
Zhou, D., Wu, Y., Jiang, K., Xu, F., Hong, R., & Wang, S. (2021) · Genomics · doi:10.1016/j.ygeno.2021.10.010 · Cited by 12
Novel HER-2 Targeted Therapies in Breast Cancer
Fernandes, C. L., Silva, D., & Mesquita, A. (2023) · Cancers · doi:10.3390/cancers16010087 · Cited by 13
“Ever since the development of the first HER-2-targeted drug, trastuzumab, the immune system proved to play an important role in tumor growth inhibition and apoptosis through ADCC and ADCP [17,18].”
BackgroundUpdate on current and new potential immunotherapies in breast cancer, from bench to bedside
Alaluf, E., Shalamov, M. M., & Sonnenblick, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1287824 · Cited by 12
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
Paek, K., Kim, G.-W., Ahn, S. Y., Lim, J. H., Jung, D., Kim, S., & Lee, J. H. (2019) · BioDrugs · doi:10.1007/s40259-019-00381-2 · Cited by 12
Liu, Z., Li, Y.-R., Yang, Y., Shen, X., Zhu, E., Nan, H., Wang, S., Lin, J., Yang, L., & Li, S. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100380 · Cited by 14
In vitro functional characterization of biosimilar therapeutic antibodies
Láng, J. A., Balogh, Z. C., Nyitrai, M. F., Juhász, C., Gilicze, A. K. B., Iliás, A., Zólyomi, Z., Bödör, C., & Rábai, E. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.010 · Cited by 12
Gao, Y., Li, L., Zheng, Y., Zhang, W., Niu, B., & Li, Y. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04390-8 · Cited by 11
Xu, B., Hu, X., Zheng, H. Y., Wang, X., Zhang, Q., Cui, S., Liu, D., Liao, N., Luo, R., Sun, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9331 · Cited by 11
“Withdrawal of trastuzumab treatment may also diminish its stimulatory effect on effector cells leading to decreased antibody-dependent cell-mediated cytotoxicity (ADCC) and increased tumor growth [40].”
BackgroundVelmurugan, R., Ramakrishnan, S., Kim, M., Ober, R. J., & Ward, E. S. (2018) · Traffic · doi:10.1111/tra.12552 · Cited by 10
Bernat‐Peguera, A., Trigueros, M., Ferrando‐Díez, A., Ibáñez, C., Bystrup, S., Martínez‐Cardús, A., Vila, M. M., & Martinez‐Balibrea, E. (2022) · The Breast · doi:10.1016/j.breast.2022.01.007 · Cited by 10
“It is well known that RTZ induces antibody-dependent cellular cytotoxicity (ADCC) in HER2expressing BC cells [34,35].”
BackgroundTanaka, T., Suzuki, H., Ohishi, T., Kaneko, M. K., & Kato, Y. (2023) · Cancer Science · doi:10.1111/cas.16008 · Cited by 10
Жукова, О. В., Kovaleva, T. F., Архипова, Е. В., Ryabov, S. A., & Mukhina, I. V. (2020) · Biomedical Reports · doi:10.3892/br.2020.1354 · Cited by 9
“Studies have indicated that monoclonal antibodies approved as anticancer drugs, such as rituximab and trastuzumab, exert their therapeutic effects mostly through antibody‐dependent cell phagocytosis (77,78).”
BackgroundInactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
Moasser, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1121 · Cited by 9
Differential regulation of human monocytes and NK cells by antibody-opsonized tumors
Yin, J., Albers, A. J., Smith, T. S., Riddell, G. T., & Richards, J. O. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2179-z · Cited by 10
“Clodronate depletion of monocytes was found to inhibit B-cell depletion and antibody-mediated tumor rejection in multiple tumor models, implying that monocytes are involved in antibody-mediated cellular depletion or tumor rejection, respectively [14, 15].”
InfluentialChimeric antigen receptor–based cell therapy for treating urological tumors
Tang, H., Guo, L., Zhang, W., & Tang, D. (2025) · Current Urology · doi:10.1097/cu9.0000000000000305 · Cited by 8
Kennedy, L. C., Kazerouni, A. S., Chau, B., Biswas, D., Alvarez, R., Durenberger, G., Dintzis, S. M., Stanton, S. E., Partridge, S. C., & Gadi, V. K. (2023) · Cancers · doi:10.3390/cancers15174337 · Cited by 8
Darya, G. H., Zare, O., Karbalaei‐Heidari, H. R., Zeinali, S., Sheardown, H. D., & Rastegari, B. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2347300 · Cited by 8
“…some monoclonal antibodies, such as rituximab, which is used to treat non-Hodgkin’s lymphoma, and trastuzumab which is used to treat HER2-overexpressing breast cancer, have been shown to increase macrophage phagocytosis and induce macrophage-mediated phagocytic killing in vitro and in vivo [56,57].”
BackgroundLiu, C., Yu, C., Yang, Y., Huang, J., Yu, X., Duan, M., Wang, L., & Wang, J. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108112 · Cited by 8
Aisa, A., Weng, S., Li, X., Zhang, D., & Yuan, Y. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103864 · Cited by 9
Method for Measurement of Antibody-Dependent Cellular Phagocytosis
Kamen, L. A., Ordonia, B., Myneni, S., & Chung, S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1450-1_19 · Cited by 7
Innovative approaches to immunotherapy in breast cancer
Quinn, K. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.119 · Cited by 7
Loi, M., Salvatore, G., Sottili, M., Calosi, L., Desideri, I., Becherini, C., Salvestrini, V., Ciccone, L. P., Stocchi, G., Meattini, I., et al. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02785-z · Cited by 7
“It has been proposed that macrophages can mediate antibody-dependent cellular phagocytosis (ADCP) and cancer cell killing in the presence of Trastuzumab; therefore, increased infiltration of macrophages in the tumor might be associated with improved Trastuzumab activity [19].”
BackgroundLiao, B., Tumanut, C., Li, L., Corper, A. L., Challa, D. K., Chang, A., Begum, H., Farokhi, E., Woods, C., & Fan, X. (2024) · mAbs · doi:10.1080/19420862.2024.2381261 · Cited by 6
Self-citationNami, B., & Wang, Z. (2024) · Cells · doi:10.3390/cells13171452 · Cited by 6
Zwep, L. B., Duisters, K. L. W., Jansen, M., Guo, T., Meulman, J. J., Upadhyay, P. J., & van Hasselt, J. G. C. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12603 · Cited by 7
Dual identity of tumor-associated macrophage in regulated cell death and oncotherapy
Shao, Y., Wang, Y., Su, R., Pu, W., Chen, S., Fu, L., Yu, H., & Qiu, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17582 · Cited by 7
“Anti-cancer monoclonal antibodies such as rituximab and trastuzumab have been shown to exert their therapeutic effects primarily or partially through macrophage-mediated antibody-dependent cell-mediated phagocytosis (ADCP) [136,137].”
BackgroundMasuda, Y., Yamashita, S., Nakayama, Y., Shimizu, R., & Konishi, M. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00802 · Cited by 6
The application of antibody-based agents in cancer therapy based on their mechanisms of action
Qian, K., Li, G., Zhang, S., Zou, Y., Ai, H., Zheng, X., Fu, W., Lei, C., & Hu, S. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.02.021 · Cited by 6
“…blockade of its antitumor activity was demonstrated to rely on macrophage recruitment within the tumor tissues in a macrophage-depleted breast cancer xenograft model [126] . tumor-associated CD47 expression inversely correlates with survival in HER2-positive breast cancer patients, and complete…”
Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions
Fan, X., Yuan, Z., Zhao, Y., Xiong, W., Hsiao, H., Pare, R. B., Ding, J., Almosa, A., Sun, K., Zhang, S., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03931-7 · Cited by 6
Self-citationLiang, J., Dai, W., Li, Z., Liang, X., Xiao, M., Xie, C., & Li, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-10136-y · Cited by 6
“Trastuzumab exerts several biological effects, including anti-proliferation, apoptosis activities, antibody-dependent cellular cytotoxicity and phagocytosis against HER2-positive cells, and therefore inhibits tumour growth [4, 5].”
BackgroundPhagocytic clearance of targeted cells with a synthetic ligand
Yamato, Y., & Suzuki, J. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01483-9 · Cited by 5
Fan, Y., Liao, J., Wang, Y., Wang, Z., Zheng, H. Y., & Wang, Y. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac120 · Cited by 5
Pamonsupornwichit, T., Sornsuwan, K., Juntit, O.-A., Yasamut, U., Takheaw, N., Kasinrerk, W., Wanachantararak, P., Kodchakorn, K., Nimmanpipug, P., Intasai, N., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126626 · Cited by 5
Eroğlu, G. Ö., Erol, A., Yaylım, İ., & Kuruca, S. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146876 · Cited by 4
“The in vitro co-culture model was designed with an immune cell-to-cancer cell ratio of 5:1, representing a condition in which the immune system is relatively inadequate [30,31].”
The Perils and Promise of Cellular Cannibalism in Development, Homeostasis, and Disease
Rodríguez, M. M. D., Mishra, A. K., & Montell, D. J. (2025) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101323-121655 · Cited by 4
Kim, R.-K., Heo, C.-K., Choi, M. J., Kahm, Y.-J., Kim, M., Lee, M., Lee, J. Y., Park, H., Jung, U., Shin, B.-C., et al. (2025) · Theranostics · doi:10.7150/thno.113347 · Cited by 5
“Trastuzumab (anti-HER2) is a well-established ADCC-inducing antibody [64], while ADCP plays a vital role in the efficacy of antibodies like rituximab and daratumumab [65–67].”
Lai, P. S., Usama, S. M., Kiew, L. V., Lee, H. B., Chung, L. Y., Burgess, K., & Kue, C. S. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03147-y · Cited by 4
“In comparison, non-immunized monoclonal antibodybased targeted therapy such as trastuzumab [32], alemtuzumab [33], rituximab [34] directly target surface molecules HER2, CD52 and CD20, respectively, on cancer cells.”
BackgroundThe Role of HER2 in Cancer and Its Influence on the Tumor Microenvironment
Choi, S., Kim, M., & Kim, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009458 · Cited by 5
Immunologic Approaches to Breast Cancer Therapy
Stanton, S. E., Ramos, E., & Disis, M. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00071-4 · Cited by 4
Systems Biology in Biomarker Development for Cancer Signaling Therapy
Generalov, E. A., Clarke, T., Iddamalgoda, L., Sundararajan, V. S., Suravajhala, P., & Goltsov, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813539-6.00003-1 · Cited by 4
Wieckowski, S., Avenal, C., Orjalo, A. V., Gygax, D., & Cymer, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.552596 · Cited by 4
Wang, F., Azim, Q. A., Sohail, A., Nutini, A., Arif, R., & Tavares, J. M. R. S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.08.061 · Cited by 4
Das, G., Ptáček, J., Campbell, J., Li, X., Havlínová, B., Noonepalle, S. K. R., Villagra, A., Bařinka, C., & Nováková, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0307353 · Cited by 3
HER Receptor, Current, and Emerging Therapeutic Targets
Tan, M., Yeap, J. W., & Matawali, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_258-1 · Cited by 4
Das, G., Vasquez, M., Zhang, J., Yang, W., Gao, Y., Li, X., Zhao, H., & Wong, S. T. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.23.654950 · Cited by 3
“Trastuzumab also activates antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (Petricevic et al., 2013; Shi et al., 2015), further destroying the tumor and improving chemosensitivity.”
Perurena, N., Watanabe, M., Schade, A. E., Brown, W. R., Luo, E. Y., Gardner, A., Indeglia, A., Yoshinaga, A., Sahu, R., Yang, Y., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-24-3113 · Cited by 2
Zhang, N., Jordan, R. E., & An, Z. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1122861 · Cited by 2
“It is well established that some of the IgG1 monoclonal antibody cancer therapies, such as the HER2 targeting trastuzumab depend, in part, on the antibody triggered immune effector functions including ADCC for their tumor inhibition efficacy.(10)”
BackgroundSelf-citationGutting, T., Schulte, N., Belle, S., Betge, J., Härtel, N., Wilke, J., Weers, J., Ebert, M. P. A., & Zhan, T. (2019) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-397 · Cited by 2
“In addition, FcR can induce phagocytosis of trastuzumab-coated cells [27].”
BackgroundProtocol for the murine antibody-dependent cellular phagocytosis assay
Stanganello, E., Brkic, M., Zenner, S., Beulshausen, I., Schmitt, U., & Vascotto, F. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.05.006 · Cited by 1
Chuang, C., Huang, H.-H., Wu, Y., Chen, C.-H., Weng, S.-L., Chiu, Y.-C., & Liao, K.-W. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0109 · Cited by 1
“…TAA, is overexpressed in 15% to 30% of breast cancer patients, and these patients can benefit from anti-HER2 antibody–drug therapy through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) [ 10 – 12 ].”
Riller, Q., Varthaman, A., & Sibéril, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_9 · Cited by 1
HER2-Positive (HER2 +) Breast Cancer
Dilday, T., & Yeh, E. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00055-4 · Cited by 2
Physicochemical and Functional Characterization of trastuzumab-dkst, a Trastuzumab Biosimilar
Goyal, P., Iyer, J., Adhikary, L., Vats, B., Kabadi, P. G., Pai, H. V., Ranayhossaini, D., Gouda, S., Subbarao, M., Mehta, G., et al. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0113 · Cited by 1
CLEC5a-directed bispecific antibody for effective cellular phagocytosis
Kedage, V., Ellerman, D. A., Fei, M., Liang, W., Zhang, G., Cheng, E., Zhang, J., Chen, Y., Huang, H., Lee, W. P., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2040083 · Cited by 1
Maadi, H. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-74bb-e058 · Cited by 1
Schütz, F., Stefanović, S., Sohn, C., von Au, A., Mayer, L., & Domschke, C. (2017) · Der Gynäkologe · doi:10.1007/s00129-017-4094-3
“Der Antikörper blockiert zum einen die Dimerisierung mit anderen HER2-Rezeptoren, sodass der Signalweg nicht aktiviert werden kann, und markiert zum anderen die Tumorzelle für die Zellen des Immunsystems, welche die Tumorzelle nun als fremd erkennen können [19].”
BackgroundNgambenjawong, C. (2017) · ResearchWorks at the University of Washington (University of Washington)
The Role of the Ste20-like Kinase in Embryonic Development and Neu-induced Mammary Tumorigenesis
Al‐Zahrani, K. N. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-22866 · Cited by 1
“antibody-dependent cell-mediated cytotoxicity or phagocytosis both in vitro and in vivo (110,111).”
BackgroundCombination Immunotherapy with Inhibitor of Apoptosis (IAP) Antagonists to Treat Neuroblastoma
Michalicka, M. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-22991 · Cited by 1
“Triple combination of αGD2 antibody, αPD-L1 antibody. and LCL161 further delays NXS2 s.c. tumour growth.. ........................................................................................................... 98 ix LIST OF ABBREVIATIONS ACVS Animal Care and Veterinary Service ADCC antibody dependent cellular cyto…”
BackgroundInfluentialHurtado, V. H., & Matamoros, E. K. G. (2020) · Oncología (Ecuador) · doi:10.33821/493 · Cited by 2
“A su vez estas células cubiertas de trastuzumab son fagocitadas por células dependientes de anticuerpos como los macrófagos [11].”
BackgroundHost genetic background regulates the capacity for anti-tumor antibody-dependent phagocytosisPreprint
Glassbrook, J. E., Hackett, J. B., Muñiz, M. C., Bross, M., Dyson, G. E., Movahhedin, N., Ullrich, A., & Gibson, H. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.09.540046
Viglietti, A. I. P., Bordignon, M. B., Ostinelli, A., Cueto, G., Sánchez, M. B., Perazzo, F., Amat, M., Coló, F. A., Costanzo, M. V., Nervo, A., et al. (2023) · Oncología Clínica · doi:10.56969/oc.v28i2.143
Bui, I., Vivarelli, S., Falzone, L., Libra, M., & Bonavida, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00002-6
Grechukhina, K., Sukhova, M. V., Максимовна, К. Е., Filonenko, D., & Zhukova, L. (2025) · Journal of Modern Oncology · doi:10.26442/18151434.2025.1.202822
Targeting Innate Immunity: A New Door to Cancer Therapy
Chowdhury, U., & Khadilkar, R. J. (2025) · Springer eBooks · doi:10.1007/978-981-96-7336-0_11 · Cited by 1
HER Receptor, Current, and Emerging Therapeutic Targets
Tan, M. L., Yeap, J. W., & Matawali, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_258
Consenso de cardio-oncología: Prevención, diagnóstico y tratamiento de toxicidad cardiovascular
Sacoto, K. M., Padilla, T., Mendieta, A. E. V., Grajeda, A. L. G., Abad, L., Acuña, S., Hidalgo, I. V., Aguirre, M., Bravo, L. E., Revelo, M. S. C., et al. (2025) · Metro Ciencia · doi:10.47464/metrociencia/vol33/3/2025/61-135
Bastin, N., Mezzanotte-Sharpe, J., Alvarez, R., Partridge, S. C., Dintzis, S. M., Stanton, S. E., Gadi, V., & Kennedy, L. C. (2025) · Biomedicines · doi:10.3390/biomedicines13112784
“Despite the clinical use of trastuzumab for over 25 years, the immune mechanism of action is not clearly defined, though preclinical studies suggest both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are involved [9–11].”
Re-educating macrophages to activate antitumor immunity: One Clever Immunotherapy
Viitala, M. (2023) · UTUPub (University of Turku)
Couillault, C. (2019) · theses.fr (ABES) · doi:10.70675/843d4729zb881z4e85z9bf5z1adbd72f3e7a
Etude des mécanismes de contrôle des cellules tumorales par les cellules Natural Killer
Fenis, A. (2024) · theses.fr (ABES) · doi:10.70675/747c59caz7a79z4064z989cz9dd2bc8bd27e
Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer
Poggi, A. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2026.078483
“…expressed on the NK cell by the fragment antigen binding (Fab), not by the Fc portion of the antibody, as it happens in the classical ADCC triggered by therapeutic humanized/human antibody with the appropriate isotype of Fc, like the anti-EGFR cetuximab or the anti-HER2 trastuzumab [170,171].”
Huang, P.-L., Hsieh, H.-T., Kan, H.-T., Hsu, C.-H., Huang, K.-M., Chen, H.-Y., Chen, T.-N., & You, J. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01564-8
“It is well documented that trastuzumab triggers ADCP by engaging Fcγ receptors on macrophages, thus promoting the phagocytosis of HER2-positive tumor cells (Petricevic et al. 2013; Shi et al. 2015).”
Lv, H., Zhao, W., Wang, S., He, Y., Nie, C., & Chen, X. (2026) · Gastroenterology report · doi:10.1093/gastro/goag068
George, K., Ko, S., Irani, S., Delidakis, G., Lee, C., Menon, P. S., Kim, J. E., Herpers, B. M., Rocha, E., Soto, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.31.748147
Metikala, S., Bogadi, M. R., Vemula, V. K., Kumar, D. R. Y., Patel, Y., Reddy, B., Satish, N., Vuchuru, N. R., Kayala, K. S., Yarlagadda, P., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-71292-w
“The Fc portion of trastuzumab binds to FcγRIIA receptor 11,12 .”
McRae, H. M., Nguyen, K. M., Vallmajó-Martín, Q., Rivera, S. A., Stevenson, B. T., Evensen, K. G., Burns, M. J., Bell, J. C., Mandias, H. C. R., Chick, B. Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.25.754528
Glycan-intrinsic monoclonal antibody biomanufacturing
Gyorgypal, A. (2026) · Frontiers in Chemical Engineering · doi:10.3389/fceng.2026.1955792
Metadata
- Authors
- Shi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z.
- Affiliations
- Army Medical University (CN)
- Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Shi, Yun
- Fan, Xuejun
- Deng, Hui
- Zhang, Ningyan
- An, Zhiqiang
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-01
- Volume
- 194
- Issue
- 9
- Pages
- 4379-4386
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1589766395
- Cited by
- 195
- References
- 40
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 19 · 2016: 6 · 2015: 3
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- trastuzumab, HER2-positive breast cancer, antibody-dependent cellular phagocytosis, macrophages, Fc gamma receptor, FcγRIV, FcγRIII, interferon-gamma, macrophage activation, tumor-associated macrophages, phagocytic killing, antitumor immunity
- MeSH terms
- Trastuzumab, Animals, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Cytotoxicity, Immunologic, Disease Models, Animal, Humans, Macrophages, Neoplasms, Phagocytosis, Gene Expression, Receptors, IgG, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cell Line, Tumor, Mice, Antibodies, Monoclonal, Humanized, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.